Renaissance Capital logo

JANX News

US IPO Weekly Recap: Summer’s first wave brings 10 IPOs

MQ

10 IPOs and nine SPACs went public this past week as the IPO market continues to heat up heading into summer. The IPO pipeline stayed active as well, with 12 IPOs and seven SPACs submitting initial filings. Payment card platform ...read more

Preclinical cancer biotech Janux Therapeutics prices upsized IPO at $17 high end

Janux Therapeutics logo

Janux Therapeutics, a preclinical biotech developing novel T cell engagers for solid tumors, raised $194 million by offering 11.4 million shares at $17, the high end of the range of $15 to $17. The company offered 1.9 million more shares than anticipated. At...read more

Preclinical cancer biotech Janux Therapeutics sets terms for $152 million IPO

Janux Therapeutics logo

Janux Therapeutics, a preclinical biotech developing a novel class of T cell engagers for cancer, announced terms for its IPO on Monday. The La Jolla, CA-based company plans to raise $152 million by offering 9.5 million shares at a price range of $15 to $17....read more

US IPO Week Ahead: Digital payments, mental health services, and more in a diverse 9 IPO

MQ

Updated Monday, 6/7. Nine IPOs are currently slated to raise $3.9 billion, featuring digital payments, mental health services, and more. Payments platform Marqeta (MQ) plans to raise $1.0 billion at a $12.4 billion market...read more